Nurix presents updated clinical guidance, NX-2127 Phase 1 details

Nurix Therapeutics, Inc.

Investor presentation includes updated guidance on clinical programs.
Additional detail on Phase 1 trial of NX-2127 for B-cell malignancies provided.
Meetings with analysts and investors begin November 13, 2023.

item 7.01 item 9.01

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-275300

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.